相关实验视频

Updated: Jul 17, 2025

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

构建RNA甲基化修饰与免疫相关的lncRNA分子亚型和肺腺癌的预后评分系统

Jiajing Wang¹, Jianfeng Shu²

¹Department of Clinical Laboratory, Beilun People's Hospital, Ningbo, 315000, China.

Current medicinal chemistry

|September 8, 2023

概括

这项研究确定了新的RNA甲基化修饰-免疫分子亚型和肺腺癌 (LUAD) 的预后得分. 较低的RMM-I得分表明更好的生存率和对免疫疗法和化疗的潜在敏感性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

RNA甲基化与癌症发展有关,并影响瘤微环境 (TME).
了解RNA甲基化修饰基因对于预测肺腺癌 (LUAD) 进展和治疗反应至关重要.
识别与RNA甲基化和LUAD免疫相关的预后标志物对于个性化医学至关重要.

研究的目的:

在LUAD中识别新的RNA甲基化修饰-免疫分子亚型.
开发和验证基于RNA甲基化和与免疫相关的lncRNAs的LUAD的预后得分 (RMM-I得分).
评估分子亚型,预后得分和瘤免疫微环境特征之间的关系,包括药物敏感性.

主要方法:

利用来自公共数据库的RNA-Seq数据和基因组.
进行了基因组变异分析,皮尔森相关性和一致的聚类,以定义RNA甲基化修饰-免疫分子亚型 (RMM-I).
使用COX和随机生存森林分析构建了RMM-I得分,并与ROC和Kaplan Meier生存分析验证. 评估了TME和药物敏感性.

主要成果:

在LUAD中确定了四种RMM-I分子亚型,其中RMM-I4显示出更高的生存率和免疫活性.
发现关键的免疫相关基因 (HAVCR2,CD274,CTLA-4) 在RMM-I4中激活,这表明免疫治疗的潜力.
使用7个lncRNA开发了RMM-I评分;较低的评分与更好的生存率相关,并预测了对特定化疗和免疫疗法的敏感性.

结论:

RMM-I分子亚型代表了LUAD的新分类,为疾病机制提供了更深入的见解.
RMM-I评分作为一个可靠和准确的工具,用于对LUAD患者的预后评估.
这些发现为更精确的诊断,预后和针对性治疗选择提供了基础.

关键词:

卢德. 卢德. 卢德. 卢德. 卢德. 卢德.肺部腺癌瘤是肺部腺癌.RMM-I 分子分子亚型在RMM-I中得到的分数.通过RNA甲基化.后翻译修改后的翻译修改

更多相关视频

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Author Spotlight: Decoding RNA Methylation's Role in Pancreatic Cancer - A Single-Base Resolution Study

Author Spotlight: Decoding RNA Methylation's Role in Pancreatic Cancer - A Single-Base Resolution Study

Published on: July 7, 2023

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...